Show simple item record

dc.contributor.authorPapas, Klearchos K.
dc.contributor.authorSuszynski, Thomas M.
dc.contributor.authorColton, Clark K.
dc.date.accessioned2013-05-13T19:42:51Z
dc.date.available2013-05-13T19:42:51Z
dc.date.issued2009-12
dc.identifier.issn1087-2418
dc.identifier.urihttp://hdl.handle.net/1721.1/78864
dc.descriptionAuthor Manuscript: 2010 December 1.en_US
dc.description.abstractPurpose of review: There is a critical need for meaningful viability and potency assays that characterize islet preparations for release prior to clinical islet cell transplantation (ICT). Development, testing, and validation of such assays have been the subject of intense investigation for the past decade. These efforts are reviewed, highlighting the most recent results while focusing on the most promising assays. Recent Findings: Assays based on membrane integrity do not reflect true viability when applied to either intact islets or dispersed islet cells. Assays requiring disaggregation of intact islets into individual cells for assessment introduce additional problems of cell damage and loss. Assays evaluating mitochondrial function, specifically mitochondrial membrane potential, bioenergetic status, and cellular oxygen consumption rate (OCR), especially when conducted with intact islets, appear most promising in evaluating their quality prior to ICT. Prospective, quantitative assays based on measurements of OCR with intact islets have been developed, validated and their results correlated with transplant outcomes in the diabetic nude mouse bioassay. Conclusion: More sensitive and reliable islet viability and potency tests have been recently developed and tested. Those evaluating mitochondrial function are most promising, correlate with transplant outcomes in mice, and are currently being evaluated in the clinical setting.en_US
dc.description.sponsorshipNational Center for Research Resources (U.S.) (Grant)en_US
dc.description.sponsorshipNational Institutes of Health (U.S.) (Grant U42 RR 016598–01)en_US
dc.description.sponsorshipNational Institutes of Health (U.S.) (Grant RO1-DK063108–01A1)en_US
dc.description.sponsorshipIacocca Foundationen_US
dc.description.sponsorshipSchott Foundationen_US
dc.description.sponsorshipCarol Olson Memorial Diabetes Research Funden_US
dc.language.isoen_US
dc.publisherLippincott Williams & Wilkinsen_US
dc.relation.isversionofhttp://dx.doi.org/10.1097/MOT.0b013e328332a489en_US
dc.rightsCreative Commons Attribution-Noncommercial-Share Alike 3.0en_US
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/3.0/en_US
dc.sourcePMCen_US
dc.titleIslet Assessment for Transplantationen_US
dc.typeArticleen_US
dc.identifier.citationPapas, Klearchos K, Thomas M Suszynski, and Clark K Colton 2009Islet Assessment for Transplantation. Current Opinion in Organ Transplantation 14(6): 674–682.en_US
dc.contributor.departmentMassachusetts Institute of Technology. Department of Chemical Engineeringen_US
dc.contributor.mitauthorPapas, Klearchos K.
dc.contributor.mitauthorColton, Clark K.
dc.relation.journalCurrent Opinion in Organ Transplantationen_US
dc.eprint.versionAuthor's final manuscripten_US
dc.type.urihttp://purl.org/eprint/type/JournalArticleen_US
eprint.statushttp://purl.org/eprint/status/PeerRevieweden_US
dspace.orderedauthorsPapas, Klearchos K; Suszynski, Thomas M; Colton, Clark Ken
dc.identifier.orcidhttps://orcid.org/0000-0001-8777-9632
mit.licenseOPEN_ACCESS_POLICYen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record